アジア太平洋地域のEVベースリキッドバイオプシー市場：分析・予測 (2023-2032年)

アジア太平洋のEVベースリキッドバイオプシーの市場規模は、予測期間中にCAGR21.64%で推移し、2023年の1,282万米ドルから、2032年には7,475万米ドルの規模に達すると予測されています。

同市場は、継続的な技術の進歩、医療提供者による受容の高まり、個別化医療アプローチが重視される傾向の拡大に後押しされて成長すると予測されています。

アジア太平洋地域のEVベースリキッドバイオプシー市場は著しい成長を遂げています。この成長は主に、医療技術の継続的進歩と、地域全体の医療提供者によるリキッドバイオプシー技術の採用の増加によるものです。リキッドバイオプシーは、癌の早期発見と治療効果のモニタリングのための非侵襲的方法として脚光を浴びており、同地域の医療環境における個別化医療への関心の高まりと同調しています。中国、日本、韓国などの国は、R&D活動の急増と医療システムへの先端技術の導入により、この動向の最前線にいます。さらに、同地域の大規模で多様な人口は、リキッドバイオプシー用途のための充実した患者プールを提供しています。そのため、同地域の市場は大きく成長し、企業やステークホルダーに有利な機会を提供します。

当レポートでは、アジア太平洋地域のEVベースリキッドバイオプシーの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、主要国別の詳細分析、主要企業の分析などをまとめています。

市場の分類

セグメンテーション1：国別

• 中国
• 日本
• 韓国
• オーストラリア
• インド
• シンガポール
• その他

目次

エグゼクティブサマリー

第1章 調査範囲

第2章 調査手法

第3章 市場概要

• 市場概要
• EVベースリキッドバイオプシーの現状と将来の状況
• 現在の市場規模と成長の可能性
• COVID-19によるEVベースリキッドバイオプシー市場への影響

第4章 EVの分離と分析の方法

• 概要
• 分離方法
  • 超遠心法を利用したEV分離技術
  • サイズベースの手法を利用したEV分離技術
  • 免疫親和性法を利用したEV分離技術
  • 沈降法を利用したEV分離技術
  • マイクロ流体技術を活用したEV分離技術
  • 市販キットを活用したEV分離技術
  • EV分離手法の長所と短所
  • エクソソーム単離の新しいアプローチ
• 分析方法
  • EV分析手法のメリットとデメリット

第5章 EVベースリキッドバイオプシー市場 (地域別)

• 概要
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • シンガポール
  • その他

第6章 企業プロファイル

• 企業概要

List of Figures

• Figure 1: EV-Based Liquid Biopsy Market (by Region), 2022
• Figure 2: EV-Based Liquid Biopsy Market Methodology
• Figure 3: Primary Research Methodology
• Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 5: Top-Down Approach (Segment-Wise Analysis)
• Figure 6: Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 7: Subtypes of Evs
• Figure 8: Methods of EV-Isolation from Biofluids
• Figure 9: Workflow of Differential Ultracentrifugation for Exosome Isolation
• Figure 10: Methods of EV-Analysis
• Figure 11: EV-Based Liquid Biopsy Market Snapshot (by Region)
• Figure 12: EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032
• Figure 13: Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 14: Asia-Pacific: Market Dynamics
• Figure 15: Asia-Pacific EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
• Figure 16: China EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 17: Japan EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 18: India EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 19: South Korea EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 20: Australia EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 21: Singapore EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 22: Rest-of-Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
• Figure 23: Total Number of Companies Profiled
• Figure 24: Horiba Ltd.: Product Portfolio
• Figure 25: Takara Bio Inc.: Product Portfolio

List of Tables

• Table 1: Current and Future State of EV-Based Liquid Biopsy in Industries
• Table 2: Example of Few Commercial Kits Available for EV Isolation
• Table 3: Advantages and Disadvantages of the EV Isolation Methods
• Table 4: Emerging Methods for the Isolation of Exosomes
• Table 5: Advantages and Disadvantages of Analysis Methods for Evs

“The Asia-Pacific EV-Based Liquid Biopsy Market Expected to Reach $74.75 Million by 2032.”

Introduction to Asia-Pacific EV-Based Liquid Biopsy Market

The Asia-Pacific EV-based liquid biopsy market is expected to reach $74.75 million by 2032 from $12.82 million in 2023, at a CAGR of 21.64% during the forecast period. The market for EV-based liquid biopsy is anticipated to see growth propelled by continuous technological progress, rising acceptance by healthcare providers, and an increasing emphasis on personalized medical approaches.

Market Introduction

The Asia-Pacific (APAC) region is witnessing significant growth in the EV-based liquid biopsy market. This expansion is primarily attributed to ongoing advancements in healthcare technology and the increasing adoption of liquid biopsy techniques by healthcare providers across the region. Liquid biopsies are gaining prominence as a non-invasive method for early cancer detection and monitoring treatment response, aligning with the growing focus on personalized medicine in the APAC healthcare landscape. Countries like China, Japan, and South Korea are at the forefront of this trend, with a surge in research and development activities and the incorporation of advanced technologies into healthcare systems. Additionally, the region's large and diverse population offers a substantial patient pool for liquid biopsy applications. As a result, the APAC EV-based liquid biopsy market is poised for significant growth, presenting lucrative opportunities for healthcare companies and stakeholders in the region's dynamic healthcare sector.

Market Segmentation:

Segmentation 1: by Country

• China
• Japan
• South Korea
• Australia
• India
• Singapore
• Rest-of-Asia-Pacific

How can this report add value to an organization?

Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of EVs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.

Competitive Strategy: Key players in the APAC EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the APAC EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Table of Contents

Executive Summary

1. Research Scope

• 1.1. Key Questions Answered in the Report:

2. Research Methodology

• 2.1. EV-Based Liquid Biopsy Market: Research Methodology
• 2.2. Primary Data Sources
• 2.3. Secondary Data Sources
• 2.4. Market Estimation Model
• 2.5. Criteria for Company Profiling

3. Markets Overview

• 3.1. Market Introduction
• 3.2. Current and Future State of EV-Based Liquid Biopsy in Industries
• 3.3. Current Market Size and Growth Potential, $Million, 2022-2032
• 3.4. COVID-19 Impact on EV-based Liquid Biopsy Market
  • 3.4.1. Impact on Operations
  • 3.4.2. COVID-19 Impact: Current Scenario of the Market

4. Methods of EV Isolation and Analysis

• 4.1. Overview
  • 4.1.1. Evs Introduction
• 4.2. Isolation Methods
  • 4.2.1. EV Isolation Techniques Utilizing Ultracentrifugation Methods
    • 4.2.1.1. Differential Ultracentrifugation
    • 4.2.1.2. Density Gradient Centrifugation
    • 4.2.1.3. Moving Zone or Rate-Zonal Centrifugation
    • 4.2.1.4. Isopycnic Centrifugation
  • 4.2.2. EV Isolation Techniques Utilizing Size-Based Methods
    • 4.2.2.1. Ultrafiltration
    • 4.2.2.2. Sequential Filtration
    • 4.2.2.3. Size Exclusion Chromatography (SEC)
    • 4.2.2.4. Flow Field-Flow Fractionation (FFFF)
    • 4.2.2.5. Hydrostatic Filtration Dialysis (HFD)
  • 4.2.3. EV Isolation Techniques Utilizing Immunoaffinity Methods
    • 4.2.3.1. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 4.2.3.2. Magneto-Immunoprecipitation
  • 4.2.4. EV Isolation Techniques Utilizing Precipitation Methods
    • 4.2.4.1. Polyethylene Glycol (PEG) Precipitation
    • 4.2.4.2. Lectin Induced Agglutination
  • 4.2.5. EV Isolation Techniques Utilizing Microfluidic Technology
  • 4.2.6. EV Isolation Techniques Utilizing Commercial Kits
  • 4.2.7. Advantages and Disadvantages of the EV Isolation Methods
  • 4.2.8. Novel Approaches for Exosome Isolation
• 4.3. Analysis Methods
  • 4.3.1. Advantages and Disadvantages of Analysis Methods for Evs

5. EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032

• 5.1. Overview
• 5.2. Asia-Pacific
  • 5.2.1. China
  • 5.2.2. Japan
  • 5.2.3. India
  • 5.2.4. South Korea
  • 5.2.5. Australia
  • 5.2.6. Singapore
  • 5.2.7. Rest-of-Asia-Pacific

6. Company Profiles

• 6.1. Company Overview
  • 6.1.1. Horiba Ltd.
    • 6.1.1.1. Company Overview
    • 6.1.1.2. Role of Horiba Ltd. in the EV-Based Liquid Biopsy Market
    • 6.1.1.3. Major Products: Key Specifications
    • 6.1.1.4. Key Competitors
    • 6.1.1.5. Analyst Perspective
  • 6.1.2. Takara Bio Inc.
    • 6.1.2.1. Company Overview
    • 6.1.2.2. Role of Takara Bio Inc. in the EV-Based Liquid Biopsy Market
    • 6.1.2.3. Major Products: Key Specifications
    • 6.1.2.4. Key Competitors
    • 6.1.2.5. Analyst Perspective